(Q38821339)

6 September 2017

title

Surgical management of recurrent ovarian cancer (English)

1 reference

6 September 2017

1 reference

Dong Hoon Suh

1

1 reference

6 September 2017

Hee Seung Kim

series ordinal

2

1 reference

6 September 2017

Suk-Joon Chang

series ordinal

3

1 reference

6 September 2017

Robert E Bristow

series ordinal

4

1 reference

6 September 2017

language of work or name

English

0 references

publication date

26 April 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

142

1 reference

6 September 2017

issue

2

1 reference

6 September 2017

page(s)

357-367

1 reference

Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Management strategies for recurrent platinum-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Routine Clinical Practice for Patients With Recurrent Ovarian Carcinoma: Results From the TROCADERO Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: clinical and biologic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Surgical intervention in relapsed ovarian cancer is beneficial: pro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Maximal cytoreductive effort in epithelial ovarian cancer surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary cytoreduction for ovarian cancer following cisplatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Surgical cytoreduction for recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Role of secondary cytoreductive surgery in ovarian cancer relapse: Who will benefit? A systematic analysis of 240 consecutive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Surgery for relapsed ovarian cancer: when should it be offered?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Performance of AGO score for secondary cytoreduction in a high-volume U.S. center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Tertiary cytoreduction in patients with recurrent ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

A third evaluation of tertiary cytoreduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

Ovarian cancer: the duplicity of CA125 measurement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: survey among Dutch gynecologists and medical oncologists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.04.537

10.1016/J.YGYNO.2016.04.537

7 January 2021

Identifiers

DOI

1 reference

6 September 2017

1 reference